Special post-ESMO 2024 edition !

Nov 3

Timothee Olivier and I discuss the top ESMO 2024 abstracts!

1 Comment

Sahar van Waalwijk

I was wondering why the results of NIAGARA are not even as good as the the adjuvant CheckMate 274. The rate of subsequent immunotherapy in CM-274 was as low as 26%...so let’s see how NIAGARA flows...

Expand full comment

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts